Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature

Table 1

Studies on cost effectiveness analysis of DMARDs in rheumatoid arthritis.

Authors and years of publication	Type of the drugs	Countries	Overall time	Evaluation’s model	Outcomes	Cost/Effective/Ratio
Anis et al. 1996 [13]	CyA versus AZA versus D-Pen	Canada	12 months	ITT	ICER	20,698$
Verhoeven et al. 1998 [14]	SSZ versus COMBO	Netherland	56 weeks		QALY	6511 versus 5519$
Maetzel et al. 2002 [15, 16]	LNF	Canada	12 months	ACR 20	QALY	54229$
Maetzel et al. 2002 [15, 16]	LNF versus MTX	Canada	12 months	ACR 20	QALY	3853$
Kobelt et al. 2002 [4, 17]	LNF versus MTX versus SSZ	UK	15 years	Markov	QALY	35855 versus 44988 versus 37731£
Bruns et al. 2000 [18]	MTX versus ETN versus MTX + ETN versus MTX + CyA versus HCQ + MTX + SSZ	USA	6 months	ACR 20; ACR 70WN	Tree model	1100 versus 1500$
Choi et al. 2002 [19]	MTX versus ETN versus LNF versus SSZ	USA	6 months	ACR 20; ACR 70WN	Tree model	900 versus 1500$
Osiri et al. 2007 [20]	MTX versus DMARDs	Thailand	1 year	HAQ	ICER	834 versus 2061$
Schädlich et al. 2005 [21]	MTX versus LFN	Germany	1 year	HFAQ	Tree	708 versus 2010€
Korthals-De Bos et al. 2004 [22]	COBRA versus SSZ	Netherland	28 weeks	HAQ	QALY	2578 versus 3638$
Hartman et al. 2004 [23]	MTX versus MTX + folic acid	Netherland	48 weeks	EuroQol	QALY	1398 versus 1776$
Schipper et al. 2011 [32]	MTX versus MTX + LNF versus MTX + TNF	Netherland	5 years	Markov	QALY	16620 versus 17574$

CyA: cyclosporine A; HCQ: hydroxychloroquine; TNF: tumour necrosis factor; LNF: leflunomide; MTX: methotrexate; ETN: etanercept; SSZ: sulphasalazine; DMARDs: disease modifying antirheumatic drugs; ACR: American College of Rheumatology; HAQ: health assessment questionnaire; ITT: intention to treat; QALY: quality-adjusted life years; ICER: incremental cost-effectiveness ratio HFAQ: Hannover Functional Ability Questionnaire; UK: United Kingdom; USA: Unite States of America.